Understanding Arches Trial Enzalutamide Plus Adt For Mhspc
If you are looking for information about Arches Trial Enzalutamide Plus Adt For Mhspc, you have come to the right place. Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, shares an update on the results ...
Key Takeaways about Arches Trial Enzalutamide Plus Adt For Mhspc
- Prof. Stenzl on
- Ian Davis, FRAChPM, FRACP, MBBS, PhD, of the Monash University Eastern Health Clinical School, Melbourne, Australia speaks ...
- Andrew Armstrong, MD, MS, Duke University Medical Center, Durham, NC, discusses two post hoc analyses from the
- Christopher J. Sweeney, MBBS, gives an overview of the ENZAMET study, a companion to the
- Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, presents the results of a post-hoc analysis of the
Detailed Analysis of Arches Trial Enzalutamide Plus Adt For Mhspc
Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, discusses the 5-year overall survival (OS) analysis from the ... Andrew Armstrong, MD, Duke Cancer Institute, Durham, NC, discusses the Phase III Daniel P. Petrylak, MD, examines
Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, updates us on a post-hoc analysis evaluating overall survival ...
We hope this detailed breakdown of Arches Trial Enzalutamide Plus Adt For Mhspc was helpful.